SCYX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Scynexis Inc

NASDAQ | SCYX

0.80

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$33.96M

Market Cap

-

P/E Ratio

-0.4

EPS

$1.62

52 Week High

$0.66

52 Week Low

HEALTHCARE

Sector

SCYX Chart

Recent Chart
Price Action

SCYX Technicals

Tags:

SCYX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.7M
Total Revenue $3.7M
Cost Of Revenue $0
Costof Goods And Services Sold $0
Operating Income -$37M
Selling General And Administrative $14M
Research And Development $26M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $1.7M
Interest Income $4.3M
Interest Expense $2.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.7M
Income Before Tax -$21M
Income Tax Expense $151K
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$19M
Net Income -$21M

Revenue & Profitability

Earnings Performance

SCYX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $91M
Total Current Assets $72M
Cash And Cash Equivalents At Carrying Value $16M
Cash And Short Term Investments $16M
Inventory -
Current Net Receivables $10M
Total Non Current Assets $18M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $16M
Short Term Investments $43M
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $36M
Total Current Liabilities $24M
Current Accounts Payable $4.6M
Deferred Revenue -
Current Debt -
Short Term Debt $15M
Total Non Current Liabilities $11M
Capital Lease Obligations $2.6M
Long Term Debt -
Current Long Term Debt $14M
Long Term Debt Noncurrent -
Short Long Term Debt Total $16M
Other Current Liabilities $3.4M
Other Non Current Liabilities -
Total Shareholder Equity $55M
Treasury Stock -
Retained Earnings -$377M
Common Stock $41K
Common Stock Shares Outstanding $49M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$24M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.7M
Capital Expenditures $0
Change In Receivables -
Change In Inventory $0
Profit Loss -
Cashflow From Investment $6.2M
Cashflow From Financing -$139K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$21M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.7M
Total Revenue $3.7M
Cost Of Revenue $0
Costof Goods And Services Sold $0
Operating Income -$37M
Selling General And Administrative $14M
Research And Development $26M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $1.7M
Interest Income $4.3M
Interest Expense $2.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.7M
Income Before Tax -$21M
Income Tax Expense $151K
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$19M
Net Income -$21M

SCYX News

SCYX Profile

Scynexis Inc Profile

Sector: HEALTHCARE

Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC

Scynexis Inc. is a biotechnology firm headquartered in Jersey City, New Jersey, specializing in innovative therapies for the treatment of invasive fungal infections, with a particular focus on serious yeast infections. The company’s lead product candidate, BREXAFEMME®, is the first oral therapeutic specifically indicated for the treatment of vulvovaginal candidiasis, representing a significant advancement in antifungal therapy. With a robust pipeline and a commitment to addressing unmet medical needs in infectious diseases, Scynexis is well-positioned to enhance its market presence within the evolving landscape of antifungal treatments.

VHAI
-20.00%
$0.00
VIVK
-3.01%
$0.28
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
RXRX
-7.21%
$6.29
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
PLUG
-7.01%
$3.58
YDKG
-54.14%
$0.08
IVF
+129.44%
$1.73
BYND
-22.39%
$0.52
NVTS
+4.35%
$15.82
RGTI
-12.76%
$49.15
DNN
-1.57%
$3.12
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
+0.26%
$0.71
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
F
-0.63%
$11.68
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
KVUE
-12.91%
$14.16
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
DFLI
-31.72%
$1.34
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
ETHD
+4.23%
$3.94
CLF
-3.39%
$13.47
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
AAL
-6.00%
$11.75
VSEE
-8.84%
$0.54
MARA
-10.98%
$20.32
GNPX
-47.58%
$0.44
RIG
-3.32%
$3.20
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
BTBT
-8.82%
$3.70
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
NAK
-16.47%
$2.20
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
MASK
+18.73%
$0.57
CRML
-13.51%
$19.64
RGTZ
+28.73%
$11.19
SNAP
-2.46%
$7.71
RR
-6.38%
$5.76
CIFR
-10.08%
$18.91
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
IREN
-8.20%
$62.40
GPUS
-6.53%
$0.36
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
PLTR
-0.81%
$178.16
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
JBLU
-4.94%
$4.70
AMZN
-0.81%
$213.82
SLNH
+1.86%
$4.37
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
HBAN
-4.62%
$15.46
WULF
-8.82%
$14.10
SATL
-27.65%
$2.99
AMC
-1.77%
$2.77
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
PFE
-0.12%
$24.35
KEY
-6.45%
$16.58
AG
+2.27%
$15.20
VHAI
-20.00%
$0.00
VIVK
-3.01%
$0.28
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
RXRX
-7.21%
$6.29
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
PLUG
-7.01%
$3.58
YDKG
-54.14%
$0.08
IVF
+129.44%
$1.73
BYND
-22.39%
$0.52
NVTS
+4.35%
$15.82
RGTI
-12.76%
$49.15
DNN
-1.57%
$3.12
NIO
-1.09%
$6.74
MIRA
+49.24%
$1.97
SCNX
+0.26%
$0.71
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
F
-0.63%
$11.68
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
KVUE
-12.91%
$14.16
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
DFLI
-31.72%
$1.34
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
ETHD
+4.23%
$3.94
CLF
-3.39%
$13.47
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
AAL
-6.00%
$11.75
VSEE
-8.84%
$0.54
MARA
-10.98%
$20.32
GNPX
-47.58%
$0.44
RIG
-3.32%
$3.20
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
BTBT
-8.82%
$3.70
QS
-12.89%
$15.54
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
NAK
-16.47%
$2.20
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
MASK
+18.73%
$0.57
CRML
-13.51%
$19.64
RGTZ
+28.73%
$11.19
SNAP
-2.46%
$7.71
RR
-6.38%
$5.76
CIFR
-10.08%
$18.91
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
IREN
-8.20%
$62.40
GPUS
-6.53%
$0.36
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
PLTR
-0.81%
$178.16
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
JBLU
-4.94%
$4.70
AMZN
-0.81%
$213.82
SLNH
+1.86%
$4.37
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
HBAN
-4.62%
$15.46
WULF
-8.82%
$14.10
SATL
-27.65%
$2.99
AMC
-1.77%
$2.77
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
PFE
-0.12%
$24.35
KEY
-6.45%
$16.58
AG
+2.27%
$15.20
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.